Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
ABSTRACTObjectives In the absence of head-to-head comparisons across relapsed/refractory multiple myeloma (RRMM) treatments following the approval of the oral proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone (IRd), we conducted an indirect comparison of the efficacy...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2156731 |
| _version_ | 1811170090557636608 |
|---|---|
| author | Maral DerSarkissian Holly Cranmer Jonathan Dabora Iryna Bocharova Dasha Cherepanov Mu Cheng Rachel H. Bhak Mei Sheng Duh |
| author_facet | Maral DerSarkissian Holly Cranmer Jonathan Dabora Iryna Bocharova Dasha Cherepanov Mu Cheng Rachel H. Bhak Mei Sheng Duh |
| author_sort | Maral DerSarkissian |
| collection | DOAJ |
| description | ABSTRACTObjectives In the absence of head-to-head comparisons across relapsed/refractory multiple myeloma (RRMM) treatments following the approval of the oral proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone (IRd), we conducted an indirect comparison of the efficacy of IRd relative to several RRMM therapies using Bayesian fixed-effects network meta-analysis (NMA) models.Methods Data for the NMA were obtained through a systematic literature review (conducted in June 2020), which identified randomized controlled trials (base case) and observational studies (extended network analysis) reporting overall survival (OS), progression-free survival (PFS), and overall response rate (ORR).Results In the base case, IRd was associated with a significantly longer PFS than lenalidomide and dexamethasone (Rd), bortezomib monotherapy (V), dexamethasone (Dex), and pomalidomide and dexamethasone (Pom-dex), a significantly shorter PFS than daratumumab, lenalidomide, and dexamethasone (DRd), and a PFS comparable to elotuzumab, lenalidomide, and dexamethasone (ERd) and carfilzomib, lenalidomide, and dexamethasone (KRd). IRd was associated with a significantly longer OS than V, Dex, and Pom-dex, and an OS comparable to Rd, ERd, KRd, and DRd. The ORR of IRd was significantly higher than Rd, V, and Dex, significantly lower than KRd and DRd, and comparable to Pom-dex and ERd. The extended network analyses and sensitivity analyses were consistent with the base case.Discussion This NMA shows that IRd is relatively efficacious among RRMM treatments. Being an oral regimen, IRd is also convenient to manage.Conclusion IRd could be a preferable treatment option for many patients with RRMM, particularly those seeking an efficacious and convenient therapeutic option. |
| first_indexed | 2024-04-10T16:52:52Z |
| format | Article |
| id | doaj.art-361bc79373ca4c2f849b0cf6f4bcb4e1 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-10T16:52:52Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-361bc79373ca4c2f849b0cf6f4bcb4e12023-02-07T11:14:47ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2022.2156731Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myelomaMaral DerSarkissian0Holly Cranmer1Jonathan Dabora2Iryna Bocharova3Dasha Cherepanov4Mu Cheng5Rachel H. Bhak6Mei Sheng Duh7Analysis Group, Boston, MA, USATakeda Pharmaceuticals International AG, Zurich, SwitzerlandTakeda Pharmaceuticals America, Inc., Lexington, MA, USAAnalysis Group, Boston, MA, USATakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USAAnalysis Group, Boston, MA, USAAnalysis Group, Boston, MA, USAAnalysis Group, Boston, MA, USAABSTRACTObjectives In the absence of head-to-head comparisons across relapsed/refractory multiple myeloma (RRMM) treatments following the approval of the oral proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone (IRd), we conducted an indirect comparison of the efficacy of IRd relative to several RRMM therapies using Bayesian fixed-effects network meta-analysis (NMA) models.Methods Data for the NMA were obtained through a systematic literature review (conducted in June 2020), which identified randomized controlled trials (base case) and observational studies (extended network analysis) reporting overall survival (OS), progression-free survival (PFS), and overall response rate (ORR).Results In the base case, IRd was associated with a significantly longer PFS than lenalidomide and dexamethasone (Rd), bortezomib monotherapy (V), dexamethasone (Dex), and pomalidomide and dexamethasone (Pom-dex), a significantly shorter PFS than daratumumab, lenalidomide, and dexamethasone (DRd), and a PFS comparable to elotuzumab, lenalidomide, and dexamethasone (ERd) and carfilzomib, lenalidomide, and dexamethasone (KRd). IRd was associated with a significantly longer OS than V, Dex, and Pom-dex, and an OS comparable to Rd, ERd, KRd, and DRd. The ORR of IRd was significantly higher than Rd, V, and Dex, significantly lower than KRd and DRd, and comparable to Pom-dex and ERd. The extended network analyses and sensitivity analyses were consistent with the base case.Discussion This NMA shows that IRd is relatively efficacious among RRMM treatments. Being an oral regimen, IRd is also convenient to manage.Conclusion IRd could be a preferable treatment option for many patients with RRMM, particularly those seeking an efficacious and convenient therapeutic option.https://www.tandfonline.com/doi/10.1080/16078454.2022.2156731Network meta-analysissystematic literature reviewrelapsed/refractory multiple myelomaixazomiblenalidomidedexamethasone |
| spellingShingle | Maral DerSarkissian Holly Cranmer Jonathan Dabora Iryna Bocharova Dasha Cherepanov Mu Cheng Rachel H. Bhak Mei Sheng Duh Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma Hematology Network meta-analysis systematic literature review relapsed/refractory multiple myeloma ixazomib lenalidomide dexamethasone |
| title | Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| title_full | Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| title_fullStr | Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| title_full_unstemmed | Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| title_short | Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| title_sort | network meta analysis of efficacy of ixazomib lenalidomide and dexamethasone in relapsed refractory multiple myeloma |
| topic | Network meta-analysis systematic literature review relapsed/refractory multiple myeloma ixazomib lenalidomide dexamethasone |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2022.2156731 |
| work_keys_str_mv | AT maraldersarkissian networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT hollycranmer networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT jonathandabora networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT irynabocharova networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT dashacherepanov networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT mucheng networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT rachelhbhak networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT meishengduh networkmetaanalysisofefficacyofixazomiblenalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma |